Company performance
Current Price
as of Jan 20, 2025$0.53
P/E Ratio
N/A
Market Cap
$22.19M
- ONT
Description
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Metrics
Overview
- HQMont-Saint-Guibert, WA
- SectorHealth Technology
- IndustryBiotechnology
- TickerCYAD
- Price$0.526679-1.69%
Trading Information
- Market cap$22.19M
- Float93.95%
- Average Daily Volume (1m)33,170
- Average Daily Volume (3m)92,911
- EPS-$0.33
Company
- Revenue$0.10M
- Rev growth (1yr)N/A
- Net incomeN/A
- Gross marginN/A
- EBITDA margin-9,610.78%
- EBITDAN/A
- EVN/A
- EV/Revenue203.10
- P/EN/A
- P/S294.03
- P/B6.48
Documents
Factset Street Account